Health / Medical Topics |
CDK4/6 Inhibitor LEE011
An orally available cyclin-dependent kinase (CDK) inhibitor targets at cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. CDK4/6 inhibitor LEE011 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation. (NCI Thesaurus)
YOU MAY ALSO LIKE
An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential…
Human CDK4 wild-type allele is located within 12q14 and is approximately 4 kb in length. This allele, which encodes cyclin-dependent kinase 4…
A protein kinase inhibitor specific for the cyclin-dependent kinase 4 (CDK4) with potential antineoplastic activity. CDK4 inhibitor P1446A-05 specifically inhibits CDK4-mediated G1-S…
This gene is involved in G1 stage cell cycle progression.
Human CDK3 wild-type allele is located within 17q22-qter and is approximately 27 kb in length. This allele, which encodes cyclin-dependent kinase 3…
This gene is involved in cell cycle checkpoints.